Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 11/20 | 0.50 |
| ▸ | METAP1 | P53582 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849705 | 0.98 | METAP2 (0.53) | METAP2METAP1EPHX1DPP4SLC1A3 | |
| SCHEMBL5850001 | 0.98 | METAP2 (0.53) | METAP2METAP1EPHX1DPP4SLC1A3 | |
| SCHEMBL24520309 | 0.77 | SLC1A3 (0.50) | METAP2METAP1EPHX1DPP4SLC1A3 | |
| SCHEMBL8282987 | 0.77 | EPHX1 (0.46) | METAP2METAP1EPHX1DPP4 | |
| SCHEMBL2712392 | 0.76 | DPP4 (0.41) | METAP2METAP1EPHX1DPP4SLC1A3 | |
| SCHEMBL21563502 | 0.74 | EPHX1 (0.43) | METAP2METAP1EPHX1DPP4SLC1A3 | |
| SCHEMBL623280 | 0.73 | DPP4 (0.53) | EPHX1DPP4SLC1A2SLC1A1 | |
| SCHEMBL919635 | 0.73 | DPP4 (0.53) | EPHX1DPP4SLC1A2SLC1A1 | |
| SCHEMBL1053865 | 0.73 | DPP4 (0.53) | EPHX1DPP4SLC1A2SLC1A1 | |
| SCHEMBL6257766 | 0.73 | TSHR (0.39) | METAP2METAP1EPHX1DPP4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | claimed |
| US-7030262-B2 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1546087-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | Abbott Laboratories (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004013085-A1 | 3-AMINO-2-HRYDROXYALKANOIC ACIDS AND THEIR PRODRUGS | ABBOTT LABORATORIES (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | HDGF, HCAR2, HCAR3 | METAP2 473/4885METAP1 248/4885EPHX1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.